Integrated Investment Consultants LLC Lowers Holdings in AstraZeneca PLC (NASDAQ:AZN)

Integrated Investment Consultants LLC decreased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,034 shares of the company’s stock after selling 284 shares during the quarter. Integrated Investment Consultants LLC’s holdings in AstraZeneca were worth $264,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. McClarren Financial Advisors Inc. raised its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the third quarter valued at approximately $28,000. Groupama Asset Managment raised its holdings in AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after acquiring an additional 101,225 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in AstraZeneca in the third quarter valued at approximately $45,000. Finally, Versant Capital Management Inc raised its holdings in AstraZeneca by 2,618.5% in the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after acquiring an additional 707 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $66.60 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm has a market cap of $206.50 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. The company’s 50 day simple moving average is $66.11 and its 200-day simple moving average is $74.49. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period last year, the firm posted $0.87 earnings per share. As a group, equities analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.